A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

OBJECTIVES: The WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first-in-class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and reco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Moore, Kathleen N., Gunderson, Camille, Sabbatini, Paul, McMeekin, D. Scott, Mantia-Smaldone, Gina, Burger, Robert, Morgan, Mark A., Kapoun, Ann M., Brachmann, Rainer Karl, Stagg, Robert, Farooki, Azeez, O’Cearbhaill, Roisin E
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7397408/
https://ncbi.nlm.nih.gov/pubmed/31174889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.04.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados